RNA Horizons 2024


Wednesday, September 25, 2024

RNA systems biology

Islet microexons as potential therapeutic targets in Type 2 diabetes

09:35 – 09:55

Manuel Irimia, Centre for Genomic Regulation, Barcelona, Spain

Expanding Therapeutic Horizons: The Power of RNAylation to Shape Cellular Processes

10:00 – 10:20

Katharina Höfer, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany

ADAR1, the guardian to the innate immune response

10:50 – 11:10

Mary A. O’Connell, Central European Institute of Technology (CEITEC), Brno, Czech Republic

Unlocking the Potential of Alternative Splicing for Immunotherapy Drug Discovery

11:15 – 11:35

Martin Akerman, Envisagenics Inc. New York, USA

Poster Teasers

11:40 – 12:00

The Interplay of Transcription and Splicing

13:00 – 13:20

Maria Carmo-Fonseca, Lab Institute for Molecular Medicine (IMM), University of Lisbon, Portugal


13:25 - 13:45

Ron Weiss, Massachusetts Institute of Technology, Boston, MA, USA


13:50 - 14:10


RNA therapeutics development


Opening Remarks:  Rotem Karni, Hebrew University, Faculty of Medicine, Jerusalem, Israel

Keynote Speaker

14:20 - 15:00

Adrian R. Krainer, Cold Spring Harbor Laboratory, New York, USA

The potential of individualized antisense oligonucleotide mediated exon skipping for patients with rare brain and eye disorders

15:05 - 15:25

Annemieke Aartsma-RusLeiden University, The Netherlands


16:00 - 16:20

Silvia Buonamici, Remix Therapeutics, Watertown, MA, USA


16:25 - 16:45

Masa Hagiwara, Kyoto University Graduate School of Medicine, Kyoto, Japan

Neutrophil-specific mRNA delivery - shooting at a moving target​

16:50 - 17:10

Zvika Granot, Faculty of Medicine, Hebrew University, Jerusalem, Israel


17:15 - 17:35



Thursday, September 26, 2024

RNA therapeutics development (cont.)

Splice-switching Antisense Oligonucleotide Drug Discovery for Rare Neurodegenerative Diseases

08:50 - 09:10

Michelle L. Hastings, University of Michigan, Ann Arbor, MI, USA

Modulating mRNA stability for genetic diseases and cancer therapy

09:15 - 09:35

Rotem Karni, Hebrew University, Faculty of Medicine, Jerusalem, Israel

RNA splicing in cancer

Building specificity of anti-tumor splicing inhibitors targeting SF3B1.

10:50 – 11:10

Juan Valcarcel, Centre for Genomic Regulation, Barcelona, Spain

Temperature-controlled alternative splicing: From mechanistic insights to translational research

11:15 – 11:35

Florian Heyd, Free University of Berlin, Germany

Alternative splicing of immune receptors as a regulatory mechanism

11:40 – 12:00

Michal Lotem, Hadassah Hebrew University Medical Center, Jerusalem, Israel

RNA-based strategies to target T cells to melanoma

12:00 – 12:20

Niels Schaft, University of Erlangen, Erlangen, Germany

Poster Session

12:55 - 13:30

Autism-like phenotype caused by a neuronal-microexon mis-splicing impairing kinetic stability of ribonucleoprotein condensates and regulation of mRNA translation in neurons

14:30 - 14:50

Raul Mendez, Barcelona Institute for Research in Biomedicine, Barcelona, Spain

RNA-based immunotherapy using dendritic cells or natural killer cells: from the lab to the clinic

14:55 – 15:15

Evelien Smits, University of Antwerp, Belgium

A-to-I RNA editing in cancer

15:50 – 16:10

Erez Levanon, Bar Ilan University, Ramat Gan, Israel 

Friday, September 27, 2024

CanceRNA Internal Meeting | RNA therapeutics